Vitamin D insufficiency does not affect bone mineral density response to raloxifene.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The objective of this study was to test whether the presence of vitamin D insufficiency at the initiation of raloxifene therapy affected the subsequent response of bone mineral density (BMD).

Why It Was Studied

Vitamin D insufficiency and osteoporosis are common and often coexist in postmenopausal women.

Who Took Part

According to the abstract, 7522 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are Bone Density, Drug Interactions, Estrogen Antagonists, Incidence, Osteoporosis, Postmenopause and Raloxifene Hydrochloride.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 7522 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.